 |
PDBsum entry 2rel
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Serine protease inhibitor
|
PDB id
|
|
|
|
2rel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Serine protease inhibitor
|
 |
|
Title:
|
 |
Solution structure of r-elafin, a specific inhibitor of elastase, nmr, 11 structures
|
|
Structure:
|
 |
R-elafin. Chain: a. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Other_details: the polypeptide may be obtained by expression using plasmidic expression systems in hosts such as escherichia coli and yeast, the polypeptide being also obtainable from psoriatic plaques. Patent number 5,464,822 date of patent nov. 7, 1995 by christophers
|
|
NMR struc:
|
 |
11 models
|
 |
|
Authors:
|
 |
C.Francart,M.Dauchez,A.J.P.Alix,G.Lippens
|
Key ref:
|
 |
C.Francart
et al.
(1997).
Solution structure of R-elafin, a specific inhibitor of elastase.
J Mol Biol,
268,
666-677.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
01-Apr-97
|
Release date:
|
07-Jul-97
|
|
|
Supersedes:
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P19957
(ELAF_HUMAN) -
Elafin from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
117 a.a.
57 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
268:666-677
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
Solution structure of R-elafin, a specific inhibitor of elastase.
|
|
C.Francart,
M.Dauchez,
A.J.Alix,
G.Lippens.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The solution structure of r-elafin, a specific elastase inhibitor, has been
determined using NMR spectroscopy. Characterized by a flat core and a flexible
N-terminal extremity, the three-dimensional structure is formed by a central
twisted beta-hairpin accompanied by two external segments linked by the
proteinase binding loop. A cluster of three disulfide bridges connects the
external segments to the central beta-sheet and a single fourth disulfide bridge
links the binding loop to the central beta-turn. The same spatial distribution
of disulfide bridges can be observed in both domains of the secretory leukocyte
protease inhibitor (SLPI), another elastase inhibitor. The structural homology
between r-elafin and the C-terminal domain of SLPI confirms the former as a
second member of the chelonianin family of proteinase inhibitors. Based on the
homology between the two proteins and recent results obtained for elastase
binding mutants of the bovine pancreatic trypsin inhibitor (BPTI), we define the
segment 22 to 27 as the binding loop of elafin, with the scissile peptide bond
between Ala24 and Met25. In our solution structures, this loop is extended and
solvent-exposed, and exhibits a large degree of flexibility. This mobility,
already observed for the binding loop in other protease inhibitors in solution,
might be an important feature for the interaction with the corresponding
protease.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 4.
Figure 4. HSQC spectrum of r-elafin in
2
H2O at pH 7
and at 293 K showing most of the
13
C
a
resonances, all
proline
13
C
d
resonances (Pd) and the three serine
13
C
b
resonances (Sb).
|
 |
Figure 6.
Figure 6. A representation of the different inter-proton
NOEs ( !) and the strong hydrogen bonds ( ) in
the b-sheet.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1997,
268,
666-677)
copyright 1997.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Bellemare,
N.Vernoux,
S.Morin,
S.M.Gagné,
and
Y.Bourbonnais
(2010).
Structural and antimicrobial properties of human pre-elafin/trappin-2 and derived peptides against Pseudomonas aeruginosa.
|
| |
BMC Microbiol,
10,
253.
|
 |
|
|
|
|
 |
N.Guyot,
G.Bergsson,
M.W.Butler,
C.M.Greene,
S.Weldon,
E.Kessler,
R.L.Levine,
S.J.O'Neill,
C.C.Taggart,
and
N.G.McElvaney
(2010).
Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.
|
| |
Biol Chem,
391,
705-716.
|
 |
|
|
|
|
 |
T.Kantyka,
T.Latendorf,
O.Wiedow,
J.Bartels,
R.Gläser,
G.Dubin,
J.M.Schröder,
J.Potempa,
and
U.Meyer-Hoffert
(2009).
Elafin is specifically inactivated by RgpB from Porphyromonas gingivalis by distinct proteolytic cleavage.
|
| |
Biol Chem,
390,
1313-1320.
|
 |
|
|
|
|
 |
M.T.McCrudden,
T.R.Dafforn,
D.F.Houston,
P.T.Turkington,
and
D.J.Timson
(2008).
Functional domains of the human epididymal protease inhibitor, eppin.
|
| |
FEBS J,
275,
1742-1750.
|
 |
|
|
|
|
 |
N.Guyot,
M.W.Butler,
P.McNally,
S.Weldon,
C.M.Greene,
R.L.Levine,
S.J.O'Neill,
C.C.Taggart,
and
N.G.McElvaney
(2008).
Elafin, an Elastase-specific Inhibitor, Is Cleaved by Its Cognate Enzyme Neutrophil Elastase in Sputum from Individuals with Cystic Fibrosis.
|
| |
J Biol Chem,
283,
32377-32385.
|
 |
|
|
|
|
 |
N.Sharma,
J.Kaur,
H.Xu,
N.Zur Nieden,
and
D.Rancourt
(2008).
Characterization of secretory leukocyte protease inhibitor as an inhibitor of implantation serine proteinases.
|
| |
Mol Reprod Dev,
75,
1136-1142.
|
 |
|
|
|
|
 |
T.Mizuno,
M.Muranishi,
T.Torugun,
H.Tango,
Y.Nagakane,
T.Kudeken,
Y.Kawase,
K.Kawabe,
F.Oshima,
T.Yaoi,
K.Itoh,
S.Fushiki,
and
M.Nakagawa
(2008).
Two Japanese CADASIL families exhibiting Notch3 mutation R75P not involving cysteine residue.
|
| |
Intern Med,
47,
2067-2072.
|
 |
|
|
|
|
 |
H.Xie,
S.Vucetic,
L.M.Iakoucheva,
C.J.Oldfield,
A.K.Dunker,
V.N.Uversky,
and
Z.Obradovic
(2007).
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions.
|
| |
J Proteome Res,
6,
1882-1898.
|
 |
|
|
|
|
 |
S.M.Nobar,
M.L.Zani,
C.Boudier,
T.Moreau,
and
J.G.Bieth
(2005).
Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3.
|
| |
FEBS J,
272,
5883-5893.
|
 |
|
|
|
|
 |
A.M.Torres,
H.Y.Wong,
M.Desai,
S.Moochhala,
P.W.Kuchel,
and
R.M.Kini
(2003).
Identification of a novel family of proteins in snake venoms. Purification and structural characterization of nawaprin from Naja nigricollis snake venom.
|
| |
J Biol Chem,
278,
40097-40104.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
U.Meyer-Hoffert,
N.Wichmann,
L.Schwichtenberg,
P.C.White,
and
O.Wiedow
(2003).
Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes.
|
| |
Exp Dermatol,
12,
418-425.
|
 |
|
|
|
|
 |
D.Zhang,
R.C.Simmen,
F.J.Michel,
G.Zhao,
D.Vale-Cruz,
and
F.A.Simmen
(2002).
Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes.
|
| |
J Biol Chem,
277,
29999-30009.
|
 |
|
|
|
|
 |
Z.Gáspári,
A.Patthy,
L.Gráf,
and
A.Perczel
(2002).
Comparative structure analysis of proteinase inhibitors from the desert locust, Schistocerca gregaria.
|
| |
Eur J Biochem,
269,
527-537.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Roussel,
M.Mathieu,
A.Dobbs,
B.Luu,
C.Cambillau,
and
C.Kellenberger
(2001).
Complexation of two proteic insect inhibitors to the active site of chymotrypsin suggests decoupled roles for binding and selectivity.
|
| |
J Biol Chem,
276,
38893-38898.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.C.Martins,
M.Enassar,
R.Willem,
J.M.Wieruzeski,
G.Lippens,
and
S.J.Wodak
(2001).
Solution structure of the main alpha-amylase inhibitor from amaranth seeds.
|
| |
Eur J Biochem,
268,
2379-2389.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Cierpicki,
J.Bania,
and
J.Otlewski
(2000).
NMR solution structure of Apis mellifera chymotrypsin/cathepsin G inhibitor-1 (AMCI-1): structural similarity with Ascaris protease inhibitors.
|
| |
Protein Sci,
9,
976-984.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |